One of the main reasons driving our bullish view on the Canadian cannabis industry is that medical cannabis is legal at the federal level.
Unlike what we have in the United States, Canadian cannabis companies can use banks and access basic business services allowing them to more efficiently operate. One of the companies we have been monitoring and favorable on is Emblem Corp (EMC.V) (EMMBF).
Attractive Operating Structure
Emblem is a licensed medical cannabis producer in Canada uniquely positioned within the rapidly growing medical and recreational cannabis industry. The company is focused on cannabis production through Emblem Cannabis, patient education through GrowWise Health, and pharmaceutical production through Emblem Pharmaceuticals.
We are very favorable on the company’s biotech focused initiatives and believe the market undervalues its potential. Emblem Pharmaceuticals President John Stewart is leading the launch of cannabinoid-based medications in customary pharmaceutical dosage forms such as liquids, gel caps, oral sprays, and inhalers.
Stewart has 30+ years experience developing and commercializing pharmaceutical products. He launched 11 new products (one of the most notable being OxyContin) while serving as the worldwide President and CEO of Purdue Pharma.
Meet with Emblem CEO on Monday in Miami
Emblem is led by its founders and a management team with a proven track record of success. Since inception, management has invested over $6 million in the company and executed flawlessly to create a world class facility with world class products.
On Monday, May 1st, investors interested in learning about Emblem Corp can meet with Emblem CEO Gordon Fox at American Social Bar and Grill in Miami, Florida.
Reach out to Support@mushroomstocks.com if you are interested in attending. The event is FREE to attend and food and drinks will be provided.